no desc

Cost-Effectiveness of Gliclazide - Based Intensive Glucose Control

Worldwide, over 400 million individuals have diabetes; 90% of these have type 2 diabetes mellitus (T2DM). Asian populations appear to be at higher risk of developing T2DM than other ethnic groups. The prevalence of T2DM in Vietnam is increasing rapidly. This increase has consequently created a considerable and growing economic burden in Vietnam. Therefore, a clear need exists to reduce the economic impact of the disease.

Current diabetes guidelines recommend a target glycated hemoglobin level <7.0%; there is evidence that intensive glucose control (IGC) regimes may offer benefits to patients, particularly with regard to reducing the risk of microvascular complications. ADVANCE study was a global, randomized, controlled trial designed to assess the effects of IGC on major vascular outcomes in a broad cross-section of patients with T2DM.

The objective of this analysis is to assess the cost-effectiveness of IGC vs. SGC (standard glucose control) from a Vietnamese healthcare payer perspective, using clinical outcomes identified from the ADVANCE trial. Health outcomes were expressed in terms of ESRD avoided and quality-adjusted life years (QALYs). Costs (in US $) comprised treatment costs and health state costs.

Over a 5-year horizon, IGC avoided additional ESRD events compared with SGC and provided additional QALYs. In Vietnam, gliclazide-based IGC was shown to be cost-effective compared with SGC from a healthcare payer perspective, as defined in the ADVANCE study.

SCAC 08/23 DIA 023 MPAD For the exclusive use of health professional

It can also interest you


June 6, 2023
Real-world usage of Sulfonylureas in Type 2 Diabetes (JADE register)


June 20, 2022
HbA1c variability predicts cardiovascular complications in type 2 diabetes


May 11, 2023
Cardiovascular Safety in Type 2 Diabetes with Sulfonylureas as Second-Line Drugs
Background Vimeo Live Event

Keep up to date with our content

Subscribe to our newsletter so that you are always up to date with the news.

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.